Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for
stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly …

Background: Elderly population is known to be associated with polymedication,
comorbidities and altered drug pharmacokinetics. However, the most adequate oral …

Background and Objective Atrial fibrillation (AF), the most common cardiac arrhythmia,
typically increases with age. Oral anticoagulants (OACs) are the cornerstone of treatment to …

Aging is an important risk factor for adverse events in elderly patients with atrial fibrillation
(AF) and complicates the management of anticoagulation. Underuse of oral anticoagulants …

Aims The aim of the present meta-analysis was to evaluate the efficacy and safety of non-
vitamin K oral antagonists (NOACs) vs. vitamin K antagonists (VKAs) in elderly patients with …

Vitamin K antagonists have been used for many years as the treatment of choice for long-
term oral anticoagulation in patients with non-valvular atrial fibrillation. Unfortunately, the …

Objective To investigate the influences of non–vitamin K antagonist oral anticoagulants
(NOACs) on rates of initiations of oral anticoagulants (OACs) and outcomes among elderly …

Atrial fibrillation (AF) is a common arrhythmia that is associated with an increased risk of
stroke, particularly in the elderly. Traditionally, a vitamin K antagonist such as warfarin is …

Older people, are underrepresented in randomised controlled trials of direct oral
anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study …

Aim Four non‐vitamin K oral anticoagulants (NOAC s) have been evaluated in clinical trials
for the prevention of stroke in patients with atrial fibrillation (AF). Although each of the NOAC …